Breaking News, Promotions & Moves

Ligand Pharmaceuticals Names Todd Davis CEO

Replaces John Higgins who has retired as CEO.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals has named Todd C. Davis as Chief Executive Officer. John Higgins has retired as Chief Executive Officer and will resign as a director of the company on December 31, 2022.   Mr. Davis is currently a member of Ligand’s board of directors and is Managing Partner of RoyaltyRx Capital, a special opportunities investment firm he founded in 2018.   “On behalf of the Board and everyone at Ligand, I extend our profound gratitude to John Higgins for his 16 years of exceptional s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters